Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2019 | 12-2018 | 09-2018 | 06-2018 | 03-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,934 | -43,274 | -29,214 | -17,788 | -7,483 |
| Depreciation Amortization | 19 | 29 | 15 | 6 | N/A |
| Accounts payable and accrued liabilities | -134 | 1,261 | 1,700 | -368 | 1,233 |
| Other Working Capital | 1,517 | -47 | -25 | -1,837 | 686 |
| Other Operating Activity | 1,049 | 802 | -128 | 1,523 | -1,044 |
| Operating Cash Flow | $-13,483 | $-41,229 | $-27,652 | $-18,464 | $-6,608 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -126 | -234 | -177 | -124 | N/A |
| Investing Cash Flow | $-126 | $-234 | $-177 | $-124 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 99,765 | 101,607 | N/A | N/A |
| Other Financing Activity | 0 | -1,002 | -1,002 | -1,768 | -1,641 |
| Financing Cash Flow | $N/A | $98,763 | $100,605 | $-1,768 | $-1,641 |
| Exchange Rate Effect | 13 | 56 | 32 | 24 | -20 |
| Beginning Cash Position | 147,871 | 90,515 | 90,515 | 90,515 | 90,515 |
| End Cash Position | 134,275 | 147,871 | 163,323 | 70,183 | 82,246 |
| Net Cash Flow | $-13,596 | $57,356 | $72,808 | $-20,332 | $-8,269 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,483 | -41,229 | -27,652 | -18,464 | -6,608 |
| Capital Expenditure | -126 | -234 | -177 | -124 | N/A |
| Free Cash Flow | -13,609 | -41,463 | -27,829 | -18,588 | -6,608 |